M&A Deal Summary

vivitide Acquires Peptides International

On December 16, 2019, vivitide acquired life science company Peptides International

Acquisition Highlights
  • This is vivitide’s 2nd transaction in the Life Science sector.
  • This is vivitide’s 2nd transaction in the United States.
  • This is vivitide’s 1st transaction in Kentucky.

M&A Deal Summary
Date 2019-12-16
Target Peptides International
Sector Life Science
Buyer(s) vivitide
Deal Type Add-on Acquisition

Target

Peptides International

Louisville, Kentucky, United States
Peptides International, Inc. specializes in manufacturing and distributing high purity, biologically active peptides, enzyme substrates and inhibitors, innovative polymers and related products, and custom peptide synthesis services to life sciences and research institutions throughout the world. Peptides International, Inc. was founded in 1983 and based in Louisville, Kentucky.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

vivitide

Gardner, Massachusetts, United States
Category Company
Founded 1998
Sector Life Science
DESCRIPTION

vivitide is a provider of custom peptide synthesis services, custom antibodies, catalog peptides, and biochemicals to academia, pharmaceutical, biotech, and diagnostic companies worldwide. vivitide was founded in 1998 and is based in Gardner, Massachusetts.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Kentucky) 1 of 1
Country (United States) 2 of 2
Year (2019) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-01-01 Sigma-Genosys

The Woodlands, Texas, United States

Sigma-Genosys, a division of Sigma-Aldrich (NASDAQ:SIAL), sold its custom peptide and polyclonal antibody division to NEP, retaining its other product lines.

Buy -
Mergr

Product

Company

Legal